Megan Van Etten Megan Van Etten is senior director of public affairs at PhRMA. She is responsible for leading the association’s public affairs efforts on international issues, including trade, intellectual property and access to medicines. Prior to joining PhRMA, Megan was director of media and external communications at the U.S. Chamber of Commerce and communications director at the Beer Institute. She has also worked as a communications consultant for global public relations firms. When not at the office, Megan enjoys exploring new Washington, D.C. restaurants and traveling with her husband and friends.
Recent Posts
Dose sharing as a part of the COVID-19 global vaccine equity strategy
By Megan Van Etten | July 20, 2021
The following is part of a series of Catalyst posts detailing each of the five strategies to advance COVID-19 global vaccine equity – which rely on and benefit from a strong innovation ecosystem.
Read More
Promoting global vaccine equity while protecting innovation
By Megan Van Etten | July 15, 2021
America’s biopharmaceutical companies have successfully researched, developed and distributed billions of doses of multiple vaccines and therapeutics to halt the spread of COVID-19. The...
Read More
IP Explained: How does the U.S. patent process work?
By Megan Van Etten | June 24, 2021
Have you ever used a Teflon-coated pan or hit a golf ball down the fairway? Had a friend or family member receive treatment with a new medication? All these products were developed because patents...
Read More
Supporting India during the devastating coronavirus surge
By Megan Van Etten | May 20, 2021
Like many others around the world, America’s biopharmaceutical companies stand with those affected by the coronavirus. And while biopharmaceutical companies are working around the clock to meet...
Read More
The Biden Administration allows politics to upend a pragmatic pandemic response
By Megan Van Etten | May 14, 2021
Last week, the Biden Administration announced that it will support a waiver of the World Trade Organization (WTO) Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement, which...
Read More
What they are saying: Experts highlight the importance of IP in recent NIST proposal comments
By Megan Van Etten | April 20, 2021
Strong, reliable, and clearly defined intellectual property (IP) protections are the foundation of America’s robust innovation ecosystem that patients across the globe rely on for the research and...
Read More
Key excerpts: PhRMA submits comments to NIST in effort to safeguard intellectual property protections
By Megan Van Etten | April 9, 2021
Earlier this week PhRMA submitted comments to the National Institute of Standards and Technology (NIST) regarding the proposed rulemaking on implementing regulations of the Bayh-Dole Act. Passed...
Read More
Building confidence in the COVID-19 vaccine through education
By Megan Van Etten | March 22, 2021
Throughout the COVID-19 vaccine research and development process, the biopharmaceutical industry has worked to uphold the highest standards of research, clinical testing and manufacturing.
Read More
Intellectual property is the key to vaccine development, manufacturing and technology sharing
By Megan Van Etten | March 5, 2021
Earlier today, 31 PhRMA board members signed a letter to President Joe Biden applauding the Administration’s accelerating COVID-19 vaccine rollout, but also warning against efforts to undermine...
Read More
Preserving U.S. innovation worldwide is more important than ever
By Megan Van Etten | January 29, 2021
The COVID-19 pandemic has spurred unprecedented levels of innovation within the biopharmaceutical industry to combat this urgent global health crisis. PhRMA member companies are collaborating with...
Read More
Medicare Monday (100)
340B Spotlight (46)
Cost & Consequence (0)
